JULIPTA
DEAD

Serial Number

88837713

Owner

ALLERGAN SALES, LLC

Filing Date

Mar 17, 2020

Add to watchlist:

No watchlists yet
View on USPTO

JULIPTA Trademark

Serial Number: 88837713

JULIPTA is a trademark filed by ALLERGAN SALES, LLC on March 17, 2020. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently no longer active.

Owner Contact Info

ALLERGAN SALES, LLC (490 trademarks)

5 GIRALDA FARMS
MADISON, NJ 07940

Entity Type: 16

Trademark Details

Filing Date

March 17, 2020

Registration Date

Not Registered

Published for Opposition

June 16, 2020

Goods & Services

Oral, transdermal, injectable and intravaginal contraceptive preparations; intravaginal contraceptive sponge; Hormone replacement therapy preparations; Pharmaceutical preparations for the prevention of preterm birth or pregnancy; Pharmaceutical preparations for the treatment and prevention of urinary incontinence and overactive bladder; Pharmaceutical preparations for the treatment and prevention of iron deficiency and anemia; Pharmaceutical preparations for the treatment and prevention of osteoporosis; Pharmaceutical preparations for the treatment and prevention of endometriosis; Pharmaceutical preparations for the treatment and prevention of symptoms associated with uterine fibroids; Iron chelating pharmaceutical preparations; Fertility enhancing preparations; Pharmaceuticals and medicines for the treatment and prevention of sexual dysfunction; Pharmaceuticals and medicines affecting sensory organs; Pharmaceuticals and medicines affecting the central nervous system; Pharmaceuticals and medicines affecting urogenital organs; Pharmaceuticals and medicines affecting circulatory systems; Pharmaceuticals and medicines for the treatment of cardiovascular and blood pressure diseases and disorders; Pharmaceutical preparations for the treatment and prevention of digestive tract, gastrointestinal and dermatological diseases and disorders; Pharmaceuticals and medicines for the treatment and prevention of irritable bowel syndrome; Pharmaceutical preparations that support, encourage or promote bone strength or bone health or which are used in the treatment of bone disorders or bone diseases; Antibiotics; Antifungal preparations; Antivirals and Antiprotozoals; Pharmaceutical preparations for the prevention and treatment of bacterial infections; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of neurological diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of hypertension; Pharmaceutical preparations for the prevention and treatment of Alzheimer's disease, dementia, AIDS-related dementia, CNS, neurological disorders, neurodegenerative disorders, and depression; Pharmaceuticals, namely, neuroprotective agents; antidepressants; pharmaceuticals, namely, antipsychotics; coronary vasodilating agents; Pharmaceutical preparations for the treatment of hypothyroidism; Pharmaceutical preparations for skin care used in connection with anti-aging, the treatment of glabellar lines, facial wrinkles, asymmetries and defects and conditions of the human skin, facial aesthetic surgery, facial aesthetic reconstruction, breast aesthetics; topical antibiotics, anti-inflammatories, anti-infectives, anti-glaucoma eye drops and decongestant formulations; sterile ointments for medical use; ocular wetting solutions, artificial tears and formulations pharmaceutical preparations for the treatment of minor ocular inflammations and allergic conditions; Pharmaceutical preparations for the treatment of neurological disorders, muscle dystonias, smooth muscle disorders, autonomic nerve disorders, headaches, hyperhydrosis, sports injuries, cerebral palsy, spasms, tremors and pain; dermatological formulations, namely, medicated dry skin lotions and creams, acne medications and medicated skin lighteners; Pharmaceuticals and cosmeceuticals, namely, medicated skin cleansers, toners, moisturizers, skin rejuvenators, rehydrating creams, and lotions for the face and body

Filing History

ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Sep 12, 2022 MAB6
ABANDONMENT - NO USE STATEMENT FILED
Sep 12, 2022 ABN6
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Feb 5, 2022 EXRA
SOU EXTENSION 3 GRANTED
Feb 3, 2022 EX3G
SOU EXTENSION 3 FILED
Feb 3, 2022 EXT3
SOU TEAS EXTENSION RECEIVED
Feb 3, 2022 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Aug 11, 2021 EXRA
SOU EXTENSION 2 GRANTED
Aug 9, 2021 EX2G
SOU EXTENSION 2 FILED
Aug 9, 2021 EXT2
SOU TEAS EXTENSION RECEIVED
Aug 9, 2021 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Feb 10, 2021 EXRA
SOU EXTENSION 1 GRANTED
Feb 8, 2021 EX1G
SOU EXTENSION 1 FILED
Feb 8, 2021 EXT1
SOU TEAS EXTENSION RECEIVED
Feb 8, 2021 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Aug 11, 2020 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jun 16, 2020 NPUB
PUBLISHED FOR OPPOSITION
Jun 16, 2020 PUBO
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Jun 3, 2020 CHAN
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Jun 3, 2020 TCCA
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Jun 3, 2020 COAR
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
May 27, 2020 NONP
ASSIGNED TO LIE
May 11, 2020 ALIE
APPROVED FOR PUB - PRINCIPAL REGISTER
May 2, 2020 CNSA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Apr 21, 2020 GNRN
NON-FINAL ACTION E-MAILED
Apr 21, 2020 GNRT
NON-FINAL ACTION WRITTEN
Apr 21, 2020 CNRT
ASSIGNED TO EXAMINER
Apr 21, 2020 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Mar 21, 2020 NWOS
NEW APPLICATION ENTERED
Mar 20, 2020 NWAP